发明名称 Purified antibody composition
摘要 The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
申请公布号 US9096666(B2) 申请公布日期 2015.08.04
申请号 US201414550809 申请日期 2014.11.21
申请人 AbbVie Biotechnology Ltd 发明人 Wan Min M;Avgerinos George;Zarbis-Papastoitsis Gregory
分类号 A61K39/395;C07K16/24;C07K1/18;C07K1/36;C07K16/06;A61K39/00 主分类号 A61K39/395
代理机构 Ropes & Gray LLP 代理人 Ropes & Gray LLP ;Li Z. Ying;Gavin Brendan A.
主权项 1. A liquid composition comprising adalimumab, wherein the adalimumab is expressed in a Chinese Hamster Ovary (CHO) cell expression system; and the composition is characterized in that when the composition is assayed in a cathepsin L kinetic assay, a level of cathepsin L activity less than 1.84 RFU/s/mg of adalimumab is observed, wherein the cathepsin L kinetic assay comprises: i) diluting the composition in a polystyrene container in a solution containing 25 mM NaOAc, 5 mM DTT and 1 mM EDTA at pH 5.5, ii) adding dextran sulfate to a concentration of 0.035 μg/mL and incubating at 37° C. for six hours, iii) adding Z-leucine-arginine covalently bound at its C-terminus to a fluorescent 7-amino-4-methyl coumarin (Z-leucine-arginine-AMC), wherein the diluting, adding, and incubating steps are sufficient to permit the measurement of cathepsin L hydrolysis of the Z-leucine-arginine-AMC within a linear range, and iv) measuring Z-leucine-arginine-AMC hydrolysis in the linear range in RFU/s/mg of adalimumab.
地址 Hamilton BM